Search results
Showing 1081 to 1095 of 8212 results
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)
Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer in adults.
Abaloparatide for treating osteoporosis after menopause (TA991)
Evidence-based recommendations on abaloparatide (Eladynos) for treating osteoporosis after menopause in women, trans men and non-binary people with a very high risk of fracture.
Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.
NICE is unable to make a recommendation on slow-release potassium bicarbonate–potassium citrate (Sibnayal) for treating distal renal tubular acidosis in people 1 year and over. This is because Advicenne withdrew its evidence submission.
Show all sections
Sections for TA838
Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)
Evidence-based recommendations on trastuzumab for treating advanced breast cancer in adults.
Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.
View recommendations for TA161Show all sections
Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.
View recommendations for TA160Show all sections
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)
Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)
Evidence-based recommendations on crovalimab (Piasky) for paroxysmal nocturnal haemoglobinuria in people 12 years and over.
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)
Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)
Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.
NICE is unable to recommend the use in the NHS of bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen. This is because Napp Pharmaceuticals did not provide an evidence submission.
Show all sections
Sections for TA206
NICE is unable to recommend the use in the NHS of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma. This is because Wyeth did not provide an evidence submission.
Show all sections
Sections for TA207